摘要
沙利度胺是一种致畸多种器官的致畸因子,但主要是引起肢体截肢如短肢。在二十世纪五十年代,发现啮齿目动物对沙利度胺具有抗性,这导致了动物试验的失败,以及孕妇使用该药物抗孕吐安全的致命错误。结果导致欧洲有10.000多名婴幼儿出生缺陷这成为史上最大的丑闻之一。尽管如此,沙利度胺仍然具有现代医学的地位,因为其抗炎,免疫调节和抗血管生成活性具有很强的治疗潜力,它已被FDA批准用于多发性骨髓瘤和红斑结节性红斑难治性疾病。目的是为了开发保持治疗潜力并且不致畸的衍生物,这需要关于基础分子机制的详细知识。在过去十年的破译致畸机制方面取得了很大进展。在这里,我们总结这些机制,解释啮齿动物的沙利度胺抗性,并讨论可能的机制,解释为什么药物主要针对胚胎发育中的肢体。最后,我们讨论哪些治疗和致畸机制不重叠,如果有机会可发展具有治疗潜力的非致畸性沙利度胺衍生物。
关键词: 致畸原,肢体截短,氧化应激,血管发生,CRBN,TNFα,炎症,抗癌药物。
Current Molecular Medicine
Title:The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Volume: 17 Issue: 2
关键词: 致畸原,肢体截短,氧化应激,血管发生,CRBN,TNFα,炎症,抗癌药物。
摘要: Thalidomide is a teratogen that affects many organs but primarily induces limb truncations like phocomelia. Rodents are thalidomide resistant. In the 1950s, this has led to misinterpretations of animal tests and to the fatal assumption that the drug was safe for pregnant women to use against morning sickness. The result was one of the biggest scandals in medical history: 10.000 and more infants with birth defects in Europe. Nonetheless, thalidomide still has its place in modern medicine as it has strong therapeutic potential: it has been approved by the FDA for multiple myeloma and erythema nodosum leprosum, and its anti-inflammatory, immunomodulatory and antiangiogenic activities are considered in many other refractory diseases. The aim is to develop derivatives that are not teratogenic but maintain the therapeutic potential. This requires detailed knowledge about the underlying molecular mechanisms. Much progress has been made in deciphering the teratogenic mechanisms in the last decade. Here, we summarize these mechanisms, explain thalidomide resistance of rodents, and discuss possible mechanisms that could explain why the drug primarily targets the developing limb in the embryo. We also summarize the most important therapeutic mechanisms. Finally, we discuss which therapeutic and teratogenic mechanisms do and do not overlap, and if there is a chance for the development of non-teratogenic thalidomide derivatives with therapeutic potential.
Export Options
About this article
Cite this article as:
The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine, Current Molecular Medicine 2017; 17 (2) . https://dx.doi.org/10.2174/1566524017666170331162315
DOI https://dx.doi.org/10.2174/1566524017666170331162315 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) in the Pathogenesis of Diabetic Nephropathy of Type 1 Diabetes Mellitus
Current Drug Targets Systemic Therapeutic Gene Delivery for Cancer: Crafting Paris Arrow
Current Gene Therapy Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry A Comparison of Fucoidan Conjugated to Paclitaxel and Curcumin for the Dual Delivery of Cancer Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy
Current Cancer Therapy Reviews TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry The Role of Synovial Fibroblasts in Mediating Joint Destruction in Rheumatoid Arthritis
Current Pharmaceutical Design Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science QSAR Study and Design of Novel Organoselenium and α-Tocopherol Derivatives with Enhanced Chemotherapeutic Activity
Letters in Drug Design & Discovery Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Recent Advances in Designing Substrate-Competitive Protein Kinase Inhibitors
Current Pharmaceutical Design